Speciality
Spotlight

 




           

Clinical Pharmacology

       

     





A
New Antimalarial

   

  • Talking
    Points,

    ‘Even with a dose of 62.5mg tafenoquine daily for 3 days, no reinfection
    occurred during the first 7 weeks.

     



    Tafenoquine,
    a new synthetic derivative of primaquine, retains the useful
    properties but has a much longer half-life.
    None of the volunteers who received doses of 125mg daily for
    3 days became infected during the next 77 days.

       



  
 



 

     

Speciality Spotlight

 

           
Clinical Pharmacology
       

     

A New Antimalarial
   

  • Talking Points,
    ‘Even with a dose of 62.5mg tafenoquine daily for 3 days, no reinfection occurred during the first 7 weeks.
     
    Tafenoquine, a new synthetic derivative of primaquine, retains the useful properties but has a much longer half-life. None of the volunteers who received doses of 125mg daily for 3 days became infected during the next 77 days.
       

    

 

By |2022-07-20T16:42:15+00:00July 20, 2022|Uncategorized|Comments Off on A New Antimalarial

About the Author: